-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AKweNprekU0UlLRnlbKvksBxIo2fmp2f6kPjII7daAYyucV7gkRZSHH6V8YDKB7w
 qVYuB7/mwI/zKUiswoovBQ==

<SEC-DOCUMENT>0001075880-07-000053.txt : 20071024
<SEC-HEADER>0001075880-07-000053.hdr.sgml : 20071024
<ACCEPTANCE-DATETIME>20071024075350
ACCESSION NUMBER:		0001075880-07-000053
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20071024
FILED AS OF DATE:		20071024
DATE AS OF CHANGE:		20071024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		071186901

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20071025.htm
<DESCRIPTION>FORM 6K 2007 10 25
<TEXT>
<html>

  <head>
    <title>form6k20071025.htm</title>
<!-- Licensed to: Novogen Limited-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>______________________________________________</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Form
      6-K</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>REPORT
      OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
      THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">For
      the
      month of October, 2007</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Commission
      File Number <font style="DISPLAY: inline; FONT-FAMILY: Arial, sans-serif;">________________</font></font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;">140
      Wicks
      Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Address
      of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">___________________________________</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Form
      20-F
<font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font><strong>&#160;</strong>Form
      40-F <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(l):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
      6-K if submitted solely to provide an attached annual report to security
      holders.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule lO1(b)(7):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
      which the registrant&#8217;s securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant&#8217;s security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font><strong>&#160;</strong>No
      <font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf </strong>by the undersigned,
      thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>/s/&#160;&#160;Ron
      Erratt</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Ronald
      Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Company
      Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Date
      24 October, 2007</strong></font></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div>&#160;</div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>ASX
      &amp; MEDIA RELEASE</strong></font></div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>24
        OCTOBER, 2007</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>NOVOGEN
        NV-128 INDUCES NOVEL MODE OF CELL DEATH IN CANCER CELLS</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(San
        Francisco &#8211; 24 October) - Laboratory studies presented late yesterday at the
        annual AACR/EORTC/NCI Molecular Targets and Cancer Therapeutics conference,
        demonstrate that the Novogen drug candidate NV-128 induces autophagy, a novel
        mode of cell death in multi-drug resistant ovarian cancer cells. The data
        were
        presented by Gil Mor, MD, Associate Professor, Department of Obstetrics and
        Gynecology, Yale University School of Medicine.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">NV-128
        is
        a derivative of phenoxodiol, an investigational drug licensed by Novogen
        Limited
        (ASX: NRT&#160;&#160;NASDAQ: NVGN) to Marshall Edwards, Inc. (NASDAQ: MSHL) that
        is now in Phase III clinical development for patients with late stage ovarian
        cancer.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Whereas
        phenoxodiol induces caspase-mediated apoptosis, which is often non-functional
        in
        highly chemoresistant cancer cells due to highly over-expressed anti-apoptotic
        proteins, NV-128 has been shown to induce caspase-independent DNA degradation
        and cancer cell death.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">&#8220;The
        identification of a compound that is able to invoke cancer cell death via
        a
        pathway that is not compromised in highly chemoresistant ovarian cancer cells,
        and not reliant on combination therapy with cytotoxic drugs has the potential
        to
        provide a significant benefit for treating late stage ovarian cancer patients
        for whom there are limited treatment options,&#8221; said Dr. Mor.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Importantly,
        these data demonstrate that the Novogen proprietary molecular scaffold can
        be
        synthetically modified to yield new molecules that are biologically active,
        and
        have the potential for diverse application in the clinic.&#160;&#160;Another
        phenoxodiol derivative, NV-196 is also being developed under license to Marshall
        Edwards, Inc., as a therapy for late stage chemoresistant pancreatic and
        bile
        duct cancers.&#160;&#160;NV -128 is the next drug candidate being developed from
        the Novogen technology platform.&#160;&#160;This portfolio of oncology drugs
        will become available for licensing to Marshall Edwards, Inc. when each drug
        enters human clinical trials, under the &#8220;first right and last right&#8221; option
        agreement held by Marshall Edwards, Inc.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Multinational
        Trial Underway</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phenoxodiol
        in combination with carboplatin is currently being studied
        in<strong>&#160;</strong>a multi-national Phase III clinical trial called the
        OVATURE (<strong>OVA</strong>rian<strong> TU</strong>mor<strong>
        RE</strong>sponse) Trial, following positive findings of previous trials
        conducted in Australia and at Yale-New Haven Hospital.&#160;&#160;The OVATURE
        trial is taking place at up to 60 clinical sites in the United States, Europe,
        and Australia.&#160;&#160;Preliminary results from the trial are expected within
        18 months.&#160;&#160;For more information on the trial, visit
<u>www.OVATUREtrial.com</u>.</font></div>
      <div><br></div>
      <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
        phenoxodiol and NV-128:</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phenoxodiol
        is being developed as a therapy for late-stage, chemo-resistant prostate,
        ovarian and cervical cancers.&#160;&#160;Phenoxodiol is an investigational drug
        and, as such, is not commercially available.&#160;&#160;It is a novel-acting
        drug that inhibits key pro-survival signalling pathways operating via
        sphingosine-1-phosphate and Akt.&#160;&#160;Inhibition of these pathways leads
        to prevention of phosphorylation of key anti-apoptotic proteins such as
        XIAP.&#160;&#160;Loss of activity of these proteins restores the ability of
        chemoresistant tumour cells to undergo apoptosis in response to
        chemotherapy.&#160;&#160;The putative molecular target for phenoxodiol is a
        tumour-specific protein, accounting for the highly selective nature of the
        drug.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">In
        contrast to phenoxodiol, NV-128 has been shown to induce caspase-independent
        DNA
        degradation and cancer cell death via a pathway involving pAKT down-regulation,
        LC3 cleavage to LC3-II, and the translocation of Beclin to the mitochondria
        resulting in Bcl2 inactivation and nuclear translocation of
        EndoG.&#160;&#160;This offers an opportunity for use as a monotherapy in
        chemoresistant cancers and enhanced efficacy against cancer targets less
        susceptible to phenoxodiol.&#160;&#160;The option for co-administration of both
        drugs is also under investigation to extend the potential therapeutic range
        of
        this unique class of oncology compounds.</font></div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
        Novogen and Marshall Edwards, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Novogen
        is an Australian based biotechnology company in the business of research
        and
        development of drugs derived from its phenolic technology platform. The Company
        manages its research and development programs using the expertise and clinical
        research capabilities of universities and hospitals in Australia, the US
        and
        Europe. Novogen's drug program is researching and developing compounds for
        the
        treatment of cancer, cardiovascular disease, inflammatory bowel disease and
        osteoarthritis. To date Novogen has had 77 patents granted and a further
        230
        patents are pending.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Novogen
        is the world leader in isoflavone research. From its original technology
        platform of natural isoflavones (represented in OTC products such as Promensil)
        the Company has developed a discovery program surrounding novel chemical
        entities based on a flavonoid scaffold. One of these compounds, phenoxodiol,
        is
        currently in a Phase III clinical trial for treatment of late stage ovarian
        cancer and a Phase II trial for prostate cancer. Marshall Edwards, Inc. is
        majority owned by Novogen Limited, and has licensed rights from Novogen to
        bring
        three oncology drugs &#8211; phenoxodiol, NV-196 and NV-143 &#8211; to market
        globally.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">More
        information on phenoxodiol and on the Novogen group of companies can be found
        at
<u>www.marshalledwardsinc.com</u> and <u>www.novogen.com</u>.</font></div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>Under
        U.S. law, a new drug cannot be marketed until it has been investigated in
        clinical trials and approved by the FDA as being safe and effective for the
        intended use. Statements included in this press release that are not historical
        in nature are "forward-looking statements" within the meaning of the "safe
        harbor" provisions of the Private Securities Litigation Reform Act of 1995.
        You
        should be aware that our actual results could differ materially from those
        contained in the forward-looking statements, which are based on management's
        current expectations and are subject to a number of risks and uncertainties,
        including, but not limited to, our failure to successfully commercialize
        our
        product candidates; costs and delays in the development and/or FDA approval,
        or
        the failure to obtain such approval, of our product candidates; uncertainties
        in
        clinical trial results; our inability to maintain or enter into, and the
        risks
        resulting from our dependence upon, collaboration or contractual arrangements
        necessary for the development, manufacture, commercialization, marketing,
        sales
        and distribution of any products; competitive factors; our inability to protect
        our patents or proprietary rights and obtain necessary rights to third party
        patents and intellectual property to operate our business; our inability
        to
        operate our business without infringing the patents and proprietary rights
        of
        others; general economic conditions; the failure of any products to gain
        market
        acceptance; our inability to obtain any additional required financing;
        technological changes; government regulation; changes in industry practice;
        and
        one-time events. We do not intend to update any of these factors or to publicly
        announce the results of any revisions to these forward-looking
        statements.</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div><br></div>
    <div><br>&#160;</div><br></body>
</html>



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
